NASDAQ:UBX - Unity Biotechnology Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $12.07 -0.05 (-0.41 %) (As of 11/20/2018 04:00 PM ET)Previous Close$12.12Today's Range$11.60 - $12.2752-Week Range$10.33 - $24.56Volume80,956 shsAverage Volume99,984 shsMarket Capitalization$519.72 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Unity Biotechnology, Inc., a preclinical biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 for musculoskeletal disease with an initial focus on osteoarthritis; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in Brisbane, California. Receive UBX News and Ratings via Email Sign-up to receive the latest news and ratings for UBX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:UBX Previous Symbol CUSIPN/A WebN/A PhoneN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous EmployeesN/A Outstanding Shares42,320,000Market Cap$519.72 million OptionableNot Optionable Unity Biotechnology (NASDAQ:UBX) Frequently Asked Questions What is Unity Biotechnology's stock symbol? Unity Biotechnology trades on the NASDAQ under the ticker symbol "UBX." How were Unity Biotechnology's earnings last quarter? Unity Biotechnology Inc (NASDAQ:UBX) announced its quarterly earnings data on Wednesday, November, 7th. The company reported ($0.43) EPS for the quarter, missing the Zacks' consensus estimate of ($0.30) by $0.13. View Unity Biotechnology's Earnings History. When is Unity Biotechnology's next earnings date? Unity Biotechnology is scheduled to release their next quarterly earnings announcement on Wednesday, February 6th 2019. View Earnings Estimates for Unity Biotechnology. What price target have analysts set for UBX? 4 analysts have issued twelve-month price objectives for Unity Biotechnology's stock. Their predictions range from $17.00 to $33.00. On average, they expect Unity Biotechnology's share price to reach $26.75 in the next year. This suggests a possible upside of 121.6% from the stock's current price. View Analyst Price Targets for Unity Biotechnology. What is the consensus analysts' recommendation for Unity Biotechnology? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Unity Biotechnology. Has Unity Biotechnology been receiving favorable news coverage? Media headlines about UBX stock have been trending negative recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Unity Biotechnology earned a media sentiment score of -2.4 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days. Who are some of Unity Biotechnology's key competitors? Some companies that are related to Unity Biotechnology include Arena Pharmaceuticals (ARNA), Amicus Therapeutics (FOLD), Madrigal Pharmaceuticals (MDGL), Opko Health (OPK), Medpace (MEDP), Aerie Pharmaceuticals (AERI), Endocyte (ECYT), NxStage Medical (NXTM), CONMED (CNMD), Crispr Therapeutics (CRSP), TESARO (TSRO), Pacira Pharmaceuticals (PCRX), Tandem Diabetes Care (TNDM), Global Blood Therapeutics (GBT) and INDIVIOR PLC/S (INVVY). Who are Unity Biotechnology's key executives? Unity Biotechnology's management team includes the folowing people: Mr. Keith R. Leonard Jr., Exec. Chairman & CEO (Age 56)Dr. Nathaniel E. David, Co-Founder, Pres & Director (Age 50)Dr. Jan M. van Deursen, FounderDr. Judith Campisi Ph.D., FounderMr. Daohong Zhou M.D., Founder When did Unity Biotechnology IPO? (UBX) raised $85 million in an initial public offering on Thursday, May 3rd 2018. The company issued 5,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup served as the underwriters for the IPO and Mizuho Securities was co-manager. When did the company's lock-up period expire? Unity Biotechnology's lock-up period expired on Tuesday, October 30th. Unity Biotechnology had issued 5,000,000 shares in its public offering on May 3rd. The total size of the offering was $85,000,000 based on an initial share price of $17.00. Since the end of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted. Who are Unity Biotechnology's major shareholders? Unity Biotechnology's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (8.42%), Capital World Investors (2.45%), EcoR1 Capital LLC (2.29%), BlackRock Inc. (0.81%), Artal Group S.A. (0.12%) and Bank of New York Mellon Corp (0.04%). Which institutional investors are selling Unity Biotechnology stock? UBX stock was sold by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC and Artal Group S.A.. Which institutional investors are buying Unity Biotechnology stock? UBX stock was purchased by a variety of institutional investors in the last quarter, including Capital World Investors, BlackRock Inc., FMR LLC and Bank of New York Mellon Corp. How do I buy shares of Unity Biotechnology? Shares of UBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Unity Biotechnology's stock price today? One share of UBX stock can currently be purchased for approximately $12.07. How big of a company is Unity Biotechnology? Unity Biotechnology has a market capitalization of $519.72 million. MarketBeat Community Rating for Unity Biotechnology (NASDAQ UBX)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 28 (Vote Outperform)Underperform Votes: 29 (Vote Underperform)Total Votes: 57MarketBeat's community ratings are surveys of what our community members think about Unity Biotechnology and other stocks. Vote "Outperform" if you believe UBX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe UBX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/20/2018 by MarketBeat.com StaffFeatured Article: Does the discount rate affect the economy?